Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

NCT07777211 is registered in ClinicalTrials.gov with Beijing Gene Key Life Technology Co., Ltd as lead sponsor.

NCT NCT07777211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Lead sponsor
Beijing Gene Key Life Technology Co., Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 14, 2025
Completion date
August 31, 2027
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer, ductal adenocarcinoma of pancreas